ПЭТ/КТ с 18F-фтордезоксиглюкозой и 11C-метионином у больных множественной миеломой после трансплантации аутологичных стволовых клеток - Журнал Терапевтический архив №7 Вопросы гематологии 2019
ПЭТ/КТ с 18F-фтордезоксиглюкозой и 11C-метионином у больных множественной миеломой после трансплантации аутологичных стволовых клеток
Соловьев М.В., Менделеева Л.П., Фирсова М.В. и др. ПЭТ/КТ с 18F-фтордезоксиглюкозой и 11C-метионином у больных множественной миеломой после трансплантации аутологичных стволовых клеток. Терапевтический архив. 2019; 91 (7): 75–82. DOI: 10.26442/00403660.2019.07.000328
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Цель исследования: сопоставить результаты визуализации опухолевого поражения методом позитронно-эмиссионной томографии, совмещенной с компьютерной томографией (ПЭТ/КТ) с 18F-фтордезоксиглюкозой (18F-ФДГ) и 11C-метионином у больных множественной миеломой (ММ) после трансплантации аутологичных гемопоэтических стволовых клеток (ауто-ТГСК).
Материалы и методы. В проспективное исследование включено 27 больных ММ, которым на 100-й день после ауто-ТГСК выполнялась ПЭТ/КТ с 18F-ФДГ и 11C-метионином. Полученные изображения оценивали визуально и полуколичественно. Выявляли очаги повышенного накопления каждого из препаратов (очаги гиперметаболизма), не связанные с его физиологическим распределением. В патологическом очаге по каждому из препаратов в автоматическом режиме рассчитывалось максимальное стандартизированное значение накопления радиофармпрепаратов (SUVmax). Проводили сопоставление результатов ПЭТ/КТ и противоопухолевого ответа, достигнутого после ауто-ТГСК согласно критериям международной рабочей группы по изучению ММ.
Результаты. После выполнения ауто-ТГСК у большинства больных (16/60%) достигнута полная ремиссия (ПР) заболевания. При использовании 18F-ФДГ патологическое накопление отмечено в 37% (n=10) случаев, ПЭТ-негативные результаты получены у 63% (n=17) больных. Очаги гиперметаболизма после применения 11C-метионина выявлены в 67% (n=18) случаев, отсутствие накопления определено у 33% (n=9) больных. При исследовании с 11C-метионином у больных ММ в 1,8 раза чаще определялись очаги патологического накопления радиофармпрепарата (p<0,02). При использовании 18F-ФДГ среднее значение SUVmax составило 1,02, в то время как среднее значение SUVmax для 11C-метионина – 2,29. При использовании 11C-метионина получены значения SUVmax, достоверно превышающие аналогичный показатель после применения 18F-ФДГ (р=0,02).
Заключение. Использование 11C-метионина при ПЭТ/КТ позволяет преодолеть ограниченные возможности 18F-ФДГ и увеличить частоту обнаружения опухолевого поражения костного мозга у больных ММ после ауто-ТГСК.
Ключевые слова: множественная миелома, позитронно-эмиссионная томография, совмещенная с компьютерной томографией, трансплантация аутологичных стволовых клеток крови.
Materials and methods. A prospective study included 27 MM patients subjected to 18F-FDG and 11C-methionine PET/CT on day 100 after auto-HSCT. Obtained images were visually and semi-quantitatively analyzed. Focal areas of increased uptake for every radiopharmaceutical agent (hypermetabolic foci) not associated with its physiological distribution were registered. Maximum Standardized Uptake Values (SUVmax) in pathological foci were automatically calculated for every radiopharmaceutical agent separately. PET/CT findings were compared to antitumor response achieved after auto-HSCT according to International MM Working Group criteria.
Results. After auto-HSCT, the majority of patients (16/60%) achieved a complete response. Abnormal 18F-FDG uptake was registered in 37% (n=10) of patients, negative PET findings were obtained in 63% (n=17) of patients. 11C-methionine PET/CT revealed hypermetabolic foci in 67% (n=18) of patients, and there was no 11C-methionine uptake in 33% (n=9). Pathological foci of radiopharmaceutical agent uptake were 1.8 times more frequently revealed using PET/CT with 11C-methionine (p<0.02). The mean SUVmax for 18F-FDG was 1.02, whereas the mean SUVmax for 11C-methionine was 2.29. The SUVmax value for 11C-methionine significantly exceeded that for 18F-FDG (р=0.02).
Conclusion. 11C-methionine PET/CT was superior to 18F-FDG overcoming its limitations and increasing the tumor detection rate in bone marrow in MM patients after auto-HSCT.
Keywords: multiple myeloma, positron emission tomography/computed tomography, autologous hematopoietic stem cell transplantation (auto-HSCT).
Материалы и методы. В проспективное исследование включено 27 больных ММ, которым на 100-й день после ауто-ТГСК выполнялась ПЭТ/КТ с 18F-ФДГ и 11C-метионином. Полученные изображения оценивали визуально и полуколичественно. Выявляли очаги повышенного накопления каждого из препаратов (очаги гиперметаболизма), не связанные с его физиологическим распределением. В патологическом очаге по каждому из препаратов в автоматическом режиме рассчитывалось максимальное стандартизированное значение накопления радиофармпрепаратов (SUVmax). Проводили сопоставление результатов ПЭТ/КТ и противоопухолевого ответа, достигнутого после ауто-ТГСК согласно критериям международной рабочей группы по изучению ММ.
Результаты. После выполнения ауто-ТГСК у большинства больных (16/60%) достигнута полная ремиссия (ПР) заболевания. При использовании 18F-ФДГ патологическое накопление отмечено в 37% (n=10) случаев, ПЭТ-негативные результаты получены у 63% (n=17) больных. Очаги гиперметаболизма после применения 11C-метионина выявлены в 67% (n=18) случаев, отсутствие накопления определено у 33% (n=9) больных. При исследовании с 11C-метионином у больных ММ в 1,8 раза чаще определялись очаги патологического накопления радиофармпрепарата (p<0,02). При использовании 18F-ФДГ среднее значение SUVmax составило 1,02, в то время как среднее значение SUVmax для 11C-метионина – 2,29. При использовании 11C-метионина получены значения SUVmax, достоверно превышающие аналогичный показатель после применения 18F-ФДГ (р=0,02).
Заключение. Использование 11C-метионина при ПЭТ/КТ позволяет преодолеть ограниченные возможности 18F-ФДГ и увеличить частоту обнаружения опухолевого поражения костного мозга у больных ММ после ауто-ТГСК.
Ключевые слова: множественная миелома, позитронно-эмиссионная томография, совмещенная с компьютерной томографией, трансплантация аутологичных стволовых клеток крови.
________________________________________________
Materials and methods. A prospective study included 27 MM patients subjected to 18F-FDG and 11C-methionine PET/CT on day 100 after auto-HSCT. Obtained images were visually and semi-quantitatively analyzed. Focal areas of increased uptake for every radiopharmaceutical agent (hypermetabolic foci) not associated with its physiological distribution were registered. Maximum Standardized Uptake Values (SUVmax) in pathological foci were automatically calculated for every radiopharmaceutical agent separately. PET/CT findings were compared to antitumor response achieved after auto-HSCT according to International MM Working Group criteria.
Results. After auto-HSCT, the majority of patients (16/60%) achieved a complete response. Abnormal 18F-FDG uptake was registered in 37% (n=10) of patients, negative PET findings were obtained in 63% (n=17) of patients. 11C-methionine PET/CT revealed hypermetabolic foci in 67% (n=18) of patients, and there was no 11C-methionine uptake in 33% (n=9). Pathological foci of radiopharmaceutical agent uptake were 1.8 times more frequently revealed using PET/CT with 11C-methionine (p<0.02). The mean SUVmax for 18F-FDG was 1.02, whereas the mean SUVmax for 11C-methionine was 2.29. The SUVmax value for 11C-methionine significantly exceeded that for 18F-FDG (р=0.02).
Conclusion. 11C-methionine PET/CT was superior to 18F-FDG overcoming its limitations and increasing the tumor detection rate in bone marrow in MM patients after auto-HSCT.
Keywords: multiple myeloma, positron emission tomography/computed tomography, autologous hematopoietic stem cell transplantation (auto-HSCT).
Список литературы
1. Лучинин А.С., Семочкин С.В., Минаева Н.В., Поздеев Н.М., Парамонов И.В. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области. Онкогематология. 2017;12(3):50-6 [Luchinin AS, Semochkin SV, Minaeva NV, Pozdeev NM, Paramonov IV. Epidemiology of Multiple Myeloma According to the Кirov Region Population Registers. Oncohematology. 2017;12(3):50-6 (In Russ.)]. doi: 10.17650/1818-8346-2017-12-3-50-56
2. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Множественная миелома: 7 лет таргетной терапии и ее результаты в Новосибирске. Клиническая онкогематология. 2015;8(3):267-73 [Pospelova TI, Skvortsova NV, Nechunaeva IN. Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results. Klin Onkogematol. 2015;8(3): 267-73 (In Russ.)]. http://bloodjournal.ru/wp-content/uploads/2015/11/4-Stra nitsy-iz-ONCO_3_20151-4.pdf
3. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28(8):1573-85. doi:10.1038/leu.2014.60
4. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014; 99(9):162-4. doi:10.3324/haematol.2014.110395
5. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-34. doi: 10.1038/leu.2016.381
6. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649
7. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4
8. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61. doi: 10.1093/ annonc/mdx096
9. Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017;31(12):2695-701. doi: 10.1038/leu.2017.173
10. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa A-MM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien M-LL, Facon T, Avet-Loiseau H, Attal M. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol. 2014;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164
11. Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017;92(8):E146-E152. doi: 10.1002/ajh.24781
12. Kaatsch P, Spix C, Hentschel S, Katalinic A, Luttmann S, Stegmaier C. Cancer in Germany. 2009/2010. Berlin, 2014:16-18.
13. Myeloma Statistics American Cancer Society - Cancer Facts &. Accessed May 15, 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Myeloma
14. Mendeleeva LP. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(1):5408. Accessed March 20, 2019. http://www.bloodjournal.org/content/130/Suppl_1/5408?sso-checked= true
15. Городецкий В.Р., Пробатова Н.А., Васильев В.И., Мухортова О.В., Асланиди И.П., Сидорова Ю.В., Рыжикова Н.В., Раденска-Лоповок С.Г., Егорова О.Н. Подкожная панникулитоподобная Т-клеточная лимфома. Собственный опыт в диагностике и лечении. Терапевтический архив. 2016;88(7):49-55 [Gorodetskiy VR, Probatova NA, Vasilyev VI, Mukhortova OV, Aslanidi IP, Sidorova YuV, Ryzhikova NV, Radenska-Lopovok SG, Egorova ON. Subcutaneous panniculitis-like T-cell lymphoma: The authors’ experience of diagnosis and treatment. Therapeutic Archive. 2016;88(7):49-55 (In Russ.)]. doi: 10.17116/terarkh201688749-55
16. Демина Е.А., Леонтьева А.А., Тумян Г.С., Рябухина Ю.Е., Медведовская Е.Г., Трофимова О.П., Сотников В.М., Ларионова В.Б., Парамонова Е.В., Манзюк Л.В., Кокосадзе Н.В., Мухортова О.В., Асланиди И.П., Зайцева А.Ю., Радкевич Л.А., Рудас М.С., Манукова В.А., Османов Е.А. Значение позитронно-эмиссионной томографии в оптимизации терапии распространенных стадий лимфомы Ходжкина с использованием интенсивной программы ЕАСОРР-14. Клиническая онкогематология. 2017;10(2):150-7 [Demina EA, Leont’eva AA, Tumyan GS, Ryabukhina YuE, Medvedovskaya EG, Trofimova OP, Sotnikov VM, Larionova VB, Paramonova EV, Manzyuk LV, Kokosadze NV, Mukhortova OV, Aslanidi IP, Zaitseva AYu, Radkevich LA, Rudas MS, Manukova VA, Osmanov EA. Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program. Clinical oncohematology. 2017;10(2):150-7 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-2-150-157
17. Kostakoglu L, Cheson BD. State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”. Front Oncol. 2013;3(212). doi: 10.3389/fonc.2013.00212
18. Meignan M, Hutchings M, Schwartz LH. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist. 2015;20(8):890-5. doi: 10.1634/theoncologist.2015-0036
19. Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci. 2017;18(2):445. doi: 10.3390/ijms18020445
20. Mukhortova О, Aslanidis I, Katunina T, Rumjantzev A, Silchenkov A, Solovev M, Mendeleeva L. PET/CT with 18F-FDG and 11C-methionine for assessment of remission status after autologous stem cell transplantation in multiple myeloma patients. Eur J Nucl Med Mol Imaging. 2017;44:383-4.
21. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819-23. doi: 10.1182/blood-2012-08-451690
22. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):538-48. doi: 10.1016/S1470-2045(14)70442-5
23. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-76. doi:10.1182/blood-2009-03-213280
24. Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. Clin Nucl Med. 2015;40(4):303-8. doi:10.1097/RLU.0000000000000696
25. Haznedar R, Akı SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046-53. doi:10.1007/s00259-011-1738-8
26. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-95. doi: 10.1182/blood-2011-06-361386
27. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):206-17. doi:10.1016/S1470-2045(17)30189-4
28. Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid J-S, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics. 2017;7(11):2956-64. doi: 10.7150/thno.20491
29. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S2, Hillengass J1, Palumbo A, Orfao A, Rajkumar SV, Miguel JS. Avet-Loiseau H30International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328-46. doi: 10.1016/S1470-2045(16)3020 6-6
30. Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma. 2013;54(7):1355-63. doi: 10.3109/ 10428194.2012.740559
31. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-5.
32. Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK. Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS One. 2013;8(12):84840. https://opus.bibliothek.uni-wuerzburg.de/opus4 wuerzburg/frontdoor/deliver/index/doc Id/11131/file/ 024_Lueckerath_PLoS.pdf
2. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Множественная миелома: 7 лет таргетной терапии и ее результаты в Новосибирске. Клиническая онкогематология. 2015;8(3):267-73 [Pospelova TI, Skvortsova NV, Nechunaeva IN. Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results. Klin Onkogematol. 2015;8(3): 267-73 (In Russ.)]. http://bloodjournal.ru/wp-content/uploads/2015/11/4-Stra nitsy-iz-ONCO_3_20151-4.pdf
3. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28(8):1573-85. doi:10.1038/leu.2014.60
4. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014; 99(9):162-4. doi:10.3324/haematol.2014.110395
5. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-34. doi: 10.1038/leu.2016.381
6. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649
7. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4
8. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61. doi: 10.1093/ annonc/mdx096
9. Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017;31(12):2695-701. doi: 10.1038/leu.2017.173
10. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa A-MM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien M-LL, Facon T, Avet-Loiseau H, Attal M. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol. 2014;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164
11. Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017;92(8):E146-E152. doi: 10.1002/ajh.24781
12. Kaatsch P, Spix C, Hentschel S, Katalinic A, Luttmann S, Stegmaier C. Cancer in Germany. 2009/2010. Berlin, 2014:16-18.
13. Myeloma Statistics American Cancer Society - Cancer Facts &. Accessed May 15, 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Myeloma
14. Mendeleeva LP. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(1):5408. Accessed March 20, 2019. http://www.bloodjournal.org/content/130/Suppl_1/5408?sso-checked= true
15. [Gorodetskiy VR, Probatova NA, Vasilyev VI, Mukhortova OV, Aslanidi IP, Sidorova YuV, Ryzhikova NV, Radenska-Lopovok SG, Egorova ON. Subcutaneous panniculitis-like T-cell lymphoma: The authors’ experience of diagnosis and treatment. Therapeutic Archive. 2016;88(7):49-55 (In Russ.)]. doi: 10.17116/terarkh201688749-55
16. [Demina EA, Leont’eva AA, Tumyan GS, Ryabukhina YuE, Medvedovskaya EG, Trofimova OP, Sotnikov VM, Larionova VB, Paramonova EV, Manzyuk LV, Kokosadze NV, Mukhortova OV, Aslanidi IP, Zaitseva AYu, Radkevich LA, Rudas MS, Manukova VA, Osmanov EA. Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program. Clinical oncohematology. 2017;10(2):150-7 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-2-150-157
17. Kostakoglu L, Cheson BD. State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”. Front Oncol. 2013;3(212). doi: 10.3389/fonc.2013.00212
18. Meignan M, Hutchings M, Schwartz LH. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist. 2015;20(8):890-5. doi: 10.1634/theoncologist.2015-0036
19. Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci. 2017;18(2):445. doi: 10.3390/ijms18020445
20. Mukhortova О, Aslanidis I, Katunina T, Rumjantzev A, Silchenkov A, Solovev M, Mendeleeva L. PET/CT with 18F-FDG and 11C-methionine for assessment of remission status after autologous stem cell transplantation in multiple myeloma patients. Eur J Nucl Med Mol Imaging. 2017;44:383-4.
21. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819-23. doi: 10.1182/blood-2012-08-451690
22. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):538-48. doi: 10.1016/S1470-2045(14)70442-5
23. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-76. doi:10.1182/blood-2009-03-213280
24. Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. Clin Nucl Med. 2015;40(4):303-8. doi:10.1097/RLU.0000000000000696
25. Haznedar R, Akı SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046-53. doi:10.1007/s00259-011-1738-8
26. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-95. doi: 10.1182/blood-2011-06-361386
27. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):206-17. doi:10.1016/S1470-2045(17)30189-4
28. Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid J-S, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics. 2017;7(11):2956-64. doi: 10.7150/thno.20491
29. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S2, Hillengass J1, Palumbo A, Orfao A, Rajkumar SV, Miguel JS. Avet-Loiseau H30International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328-46. doi: 10.1016/S1470-2045(16)3020 6-6
30. Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma. 2013;54(7):1355-63. doi: 10.3109/ 10428194.2012.740559
31. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-5.
32. Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK. Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS One. 2013;8(12):84840. https://opus.bibliothek.uni-wuerzburg.de/opus4 wuerzburg/frontdoor/deliver/index/doc Id/11131/file/ 024_Lueckerath_PLoS.pdf
2. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Множественная миелома: 7 лет таргетной терапии и ее результаты в Новосибирске. Клиническая онкогематология. 2015;8(3):267-73 [Pospelova TI, Skvortsova NV, Nechunaeva IN. Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results. Klin Onkogematol. 2015;8(3): 267-73 (In Russ.)]. http://bloodjournal.ru/wp-content/uploads/2015/11/4-Stra nitsy-iz-ONCO_3_20151-4.pdf
3. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28(8):1573-85. doi:10.1038/leu.2014.60
4. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014; 99(9):162-4. doi:10.3324/haematol.2014.110395
5. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-34. doi: 10.1038/leu.2016.381
6. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649
7. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4
8. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61. doi: 10.1093/ annonc/mdx096
9. Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017;31(12):2695-701. doi: 10.1038/leu.2017.173
10. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa A-MM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien M-LL, Facon T, Avet-Loiseau H, Attal M. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol. 2014;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164
11. Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017;92(8):E146-E152. doi: 10.1002/ajh.24781
12. Kaatsch P, Spix C, Hentschel S, Katalinic A, Luttmann S, Stegmaier C. Cancer in Germany. 2009/2010. Berlin, 2014:16-18.
13. Myeloma Statistics American Cancer Society - Cancer Facts &. Accessed May 15, 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Myeloma
14. Mendeleeva LP. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(1):5408. Accessed March 20, 2019. http://www.bloodjournal.org/content/130/Suppl_1/5408?sso-checked= true
15. Городецкий В.Р., Пробатова Н.А., Васильев В.И., Мухортова О.В., Асланиди И.П., Сидорова Ю.В., Рыжикова Н.В., Раденска-Лоповок С.Г., Егорова О.Н. Подкожная панникулитоподобная Т-клеточная лимфома. Собственный опыт в диагностике и лечении. Терапевтический архив. 2016;88(7):49-55 [Gorodetskiy VR, Probatova NA, Vasilyev VI, Mukhortova OV, Aslanidi IP, Sidorova YuV, Ryzhikova NV, Radenska-Lopovok SG, Egorova ON. Subcutaneous panniculitis-like T-cell lymphoma: The authors’ experience of diagnosis and treatment. Therapeutic Archive. 2016;88(7):49-55 (In Russ.)]. doi: 10.17116/terarkh201688749-55
16. Демина Е.А., Леонтьева А.А., Тумян Г.С., Рябухина Ю.Е., Медведовская Е.Г., Трофимова О.П., Сотников В.М., Ларионова В.Б., Парамонова Е.В., Манзюк Л.В., Кокосадзе Н.В., Мухортова О.В., Асланиди И.П., Зайцева А.Ю., Радкевич Л.А., Рудас М.С., Манукова В.А., Османов Е.А. Значение позитронно-эмиссионной томографии в оптимизации терапии распространенных стадий лимфомы Ходжкина с использованием интенсивной программы ЕАСОРР-14. Клиническая онкогематология. 2017;10(2):150-7 [Demina EA, Leont’eva AA, Tumyan GS, Ryabukhina YuE, Medvedovskaya EG, Trofimova OP, Sotnikov VM, Larionova VB, Paramonova EV, Manzyuk LV, Kokosadze NV, Mukhortova OV, Aslanidi IP, Zaitseva AYu, Radkevich LA, Rudas MS, Manukova VA, Osmanov EA. Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program. Clinical oncohematology. 2017;10(2):150-7 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-2-150-157
17. Kostakoglu L, Cheson BD. State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”. Front Oncol. 2013;3(212). doi: 10.3389/fonc.2013.00212
18. Meignan M, Hutchings M, Schwartz LH. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist. 2015;20(8):890-5. doi: 10.1634/theoncologist.2015-0036
19. Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci. 2017;18(2):445. doi: 10.3390/ijms18020445
20. Mukhortova О, Aslanidis I, Katunina T, Rumjantzev A, Silchenkov A, Solovev M, Mendeleeva L. PET/CT with 18F-FDG and 11C-methionine for assessment of remission status after autologous stem cell transplantation in multiple myeloma patients. Eur J Nucl Med Mol Imaging. 2017;44:383-4.
21. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819-23. doi: 10.1182/blood-2012-08-451690
22. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):538-48. doi: 10.1016/S1470-2045(14)70442-5
23. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-76. doi:10.1182/blood-2009-03-213280
24. Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. Clin Nucl Med. 2015;40(4):303-8. doi:10.1097/RLU.0000000000000696
25. Haznedar R, Akı SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046-53. doi:10.1007/s00259-011-1738-8
26. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-95. doi: 10.1182/blood-2011-06-361386
27. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):206-17. doi:10.1016/S1470-2045(17)30189-4
28. Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid J-S, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics. 2017;7(11):2956-64. doi: 10.7150/thno.20491
29. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S2, Hillengass J1, Palumbo A, Orfao A, Rajkumar SV, Miguel JS. Avet-Loiseau H30International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328-46. doi: 10.1016/S1470-2045(16)3020 6-6
30. Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma. 2013;54(7):1355-63. doi: 10.3109/ 10428194.2012.740559
31. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-5.
32. Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK. Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS One. 2013;8(12):84840. https://opus.bibliothek.uni-wuerzburg.de/opus4 wuerzburg/frontdoor/deliver/index/doc Id/11131/file/ 024_Lueckerath_PLoS.pdf
________________________________________________
2. Поспелова Т.И., Скворцова Н.В., Нечунаева И.Н. Множественная миелома: 7 лет таргетной терапии и ее результаты в Новосибирске. Клиническая онкогематология. 2015;8(3):267-73 [Pospelova TI, Skvortsova NV, Nechunaeva IN. Multiple Myeloma: 7-Year Experience of Applying Targeted Therapy in Novosibirsk and Its Results. Klin Onkogematol. 2015;8(3): 267-73 (In Russ.)]. http://bloodjournal.ru/wp-content/uploads/2015/11/4-Stra nitsy-iz-ONCO_3_20151-4.pdf
3. Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014;28(8):1573-85. doi:10.1038/leu.2014.60
4. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014; 99(9):162-4. doi:10.3324/haematol.2014.110395
5. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-34. doi: 10.1038/leu.2016.381
6. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953-9. doi: 10.1200/JCO.2011.37.2649
7. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4
8. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61. doi: 10.1093/ annonc/mdx096
9. Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2017;31(12):2695-701. doi: 10.1038/leu.2017.173
10. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa A-MM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien M-LL, Facon T, Avet-Loiseau H, Attal M. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo. J Clin Oncol. 2014;32(25):2712-7. doi: 10.1200/JCO.2013.54.8164
11. Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Am J Hematol. 2017;92(8):E146-E152. doi: 10.1002/ajh.24781
12. Kaatsch P, Spix C, Hentschel S, Katalinic A, Luttmann S, Stegmaier C. Cancer in Germany. 2009/2010. Berlin, 2014:16-18.
13. Myeloma Statistics American Cancer Society - Cancer Facts &. Accessed May 15, 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Myeloma
14. Mendeleeva LP. Multiple Myeloma in Russia (First Results of the Registration Trial). Blood. 2017;130(1):5408. Accessed March 20, 2019. http://www.bloodjournal.org/content/130/Suppl_1/5408?sso-checked= true
15. [Gorodetskiy VR, Probatova NA, Vasilyev VI, Mukhortova OV, Aslanidi IP, Sidorova YuV, Ryzhikova NV, Radenska-Lopovok SG, Egorova ON. Subcutaneous panniculitis-like T-cell lymphoma: The authors’ experience of diagnosis and treatment. Therapeutic Archive. 2016;88(7):49-55 (In Russ.)]. doi: 10.17116/terarkh201688749-55
16. [Demina EA, Leont’eva AA, Tumyan GS, Ryabukhina YuE, Medvedovskaya EG, Trofimova OP, Sotnikov VM, Larionova VB, Paramonova EV, Manzyuk LV, Kokosadze NV, Mukhortova OV, Aslanidi IP, Zaitseva AYu, Radkevich LA, Rudas MS, Manukova VA, Osmanov EA. Relevance of Positron-Emission Therapy for Optimization of Treatment of Advanced Hodgkin’s Lymphoma Using Intensive ЕАСОРР-14 Program. Clinical oncohematology. 2017;10(2):150-7 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-2-150-157
17. Kostakoglu L, Cheson BD. State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”. Front Oncol. 2013;3(212). doi: 10.3389/fonc.2013.00212
18. Meignan M, Hutchings M, Schwartz LH. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist. 2015;20(8):890-5. doi: 10.1634/theoncologist.2015-0036
19. Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci. 2017;18(2):445. doi: 10.3390/ijms18020445
20. Mukhortova О, Aslanidis I, Katunina T, Rumjantzev A, Silchenkov A, Solovev M, Mendeleeva L. PET/CT with 18F-FDG and 11C-methionine for assessment of remission status after autologous stem cell transplantation in multiple myeloma patients. Eur J Nucl Med Mol Imaging. 2017;44:383-4.
21. Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819-23. doi: 10.1182/blood-2012-08-451690
22. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):538-48. doi: 10.1016/S1470-2045(14)70442-5
23. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-76. doi:10.1182/blood-2009-03-213280
24. Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma. Clin Nucl Med. 2015;40(4):303-8. doi:10.1097/RLU.0000000000000696
25. Haznedar R, Akı SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38(6):1046-53. doi:10.1007/s00259-011-1738-8
26. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, Tacchetti P, Buttignol S, Perrone G, Brioli A, Pantani L, Terragna C, Carobolante F, Baccarani M, Fanin R, Fanti S, Cavo M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-95. doi: 10.1182/blood-2011-06-361386
27. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):206-17. doi:10.1016/S1470-2045(17)30189-4
28. Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid J-S, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics. 2017;7(11):2956-64. doi: 10.7150/thno.20491
29. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S2, Hillengass J1, Palumbo A, Orfao A, Rajkumar SV, Miguel JS. Avet-Loiseau H30International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328-46. doi: 10.1016/S1470-2045(16)3020 6-6
30. Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”. Leuk Lymphoma. 2013;54(7):1355-63. doi: 10.3109/ 10428194.2012.740559
31. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50-5.
32. Lückerath K, Lapa C, Spahmann A, Jörg G, Samnick S, Rosenwald A, Einsele H, Knop S, Buck AK. Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology. PLoS One. 2013;8(12):84840. https://opus.bibliothek.uni-wuerzburg.de/opus4 wuerzburg/frontdoor/deliver/index/doc Id/11131/file/ 024_Lueckerath_PLoS.pdf
Авторы
М.В. Соловьев 1, Л.П. Менделеева 1, М.В. Фирсова 1, И.П. Асланиди 2, О.В. Мухортова 2, В.Г. Савченко 1
1 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России, Москва, Россия
1 National Research Center for Hematology, Moscow, Russia;
2 Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia
1 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России, Москва, Россия
________________________________________________
1 National Research Center for Hematology, Moscow, Russia;
2 Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.